Antigen-Specific IgE Sensitization to Infectious Antigens: An Unstudied Hypothesis
The autoantibody mechanisms above are dominated by IgG (GPCR-targeting) and IgM (tissue-structural) isotypes. A distinct and largely unexamined possibility — here called the antigen-specific IgE hypothesis, and one that circulates widely in patient communities — is that a subset of post-infectious ME/CFS patients mount a Type-I (IgE-mediated) hypersensitivity response to antigens from the triggering infection itself — SARS-CoV-2 spike protein or tick-borne pathogen antigens — producing antigen-specific IgE that drives mast cell activation. This section evaluates that hypothesis against the available evidence. The conclusion is that it is biologically plausible but unstudied in ME/CFS, and is counterbalanced by replicated null findings on total and allergen-specific IgE. It is presented here as speculation and open questions, not as an evidence-supported mechanism. The non-IgE mast cell activation mechanisms covered elsewhere in this book (MCAS via substance P, CRH, IL-33, and MRGPRX2) remain the better-supported model for mast cell involvement in ME/CFS.
Two independent case-control studies found no elevation of IgE in ME/CFS. Repka-Ramirez et al. (2001) found total IgE levels identical in CFS and controls once stratified by atopic status (Repka-Ramirez et al. 2001) (certainty 0.65). Kowal et al. (2002) found allergen-specific IgE prevalence did not differ between CFS and controls (Kowal et al. 2002) (certainty 0.60). Eosinophil cationic protein — a marker of IgE-mediated mast cell/eosinophil degranulation — was also reported normal in CFS despite higher self-reported allergy (Kowal et al. 2002). This replicated null is the single most important constraint on any IgE-centric hypothesis: whatever mast cell involvement exists in ME/CFS, it is not accompanied by a general rise in IgE. Any IgE mechanism must therefore be confined to a specific antigen (not captured by total or common-allergen panels) and to a minority subset, or it does not operate at all.
Consequence: A clinician should not expect elevated IgE or positive standard allergy panels in a typical ME/CFS patient, and a normal IgE does not rule the diagnosis in or out. The popular intuition that ME/CFS patients are broadly “allergic” is not supported by the serological data.
(Origin: brainstorm.) (Certainty: 0.20.) The building blocks for antigen-specific anti-infective IgE exist, even though the assembled pathway has never been tested in ME/CFS. (1) Spike-specific IgE is real: anti-spike S1 IgE is elevated in severe acute COVID-19 and correlates with lung severity, with degranulated airway mast cells on histology (Tan et al. 2022) (certainty 0.55); IL-13 drives spike-specific IgE after even mild infection (Meltendorf et al. 2022); and anti-RBD IgE arises after natural infection and vaccination (Portilho et al. 2024). (2) Tick-induced antigen-specific IgE is firmly established in the form of alpha-gal syndrome, where tick bites induce IgE to galactose-alpha-1,3-galactose via IL-4/IL-13 signalling (Platts-Mills et al. 2025) (Wilson et al. 2024) (Nunen 2015), and Borrelia itself can carry alpha-gal on its surface (Cabezas-Cruz et al. 2021). The hypothesis is that, in a minority of post-COVID or post-tick ME/CFS patients, such antigen-specific IgE persists and chronically sensitizes mast cells, contributing to symptom maintenance. Crucially, this would be invisible to the total-IgE and common-allergen panels that returned null in Total and Allergen-Specific IgE Are Normal in ME/CFS: A Replicated Null, because those panels do not measure anti-spike or anti-alpha-gal IgE.
Falsifiable prediction: In post-infectious ME/CFS patients (COVID-triggered or tick-exposure-triggered) compared with healthy controls and with non-infectious-onset ME/CFS, antigen-specific IgE panels (anti-spike S1, anti-RBD, anti-alpha-gal) will be elevated in a definable subset (a pre-specified threshold of \(\geq\) 15%, set arbitrarily here as a falsification target rather than an empirical estimate), and within that subset will correlate with mast-cell-mediator symptom burden (flushing, urticaria, GI reactivity). Falsified if antigen-specific IgE is no more prevalent in post-infectious ME/CFS than in controls, or if present but uncorrelated with any symptom domain. The single existing data point is discouraging for a general ME/CFS claim: Giménez-Orenga et al. (2025) found anti-spike IgE higher in post-COVID condition than in prepandemic ME/CFS (Giménez-Orenga et al. 2025) — suggesting spike-specific IgE tracks recent COVID exposure rather than the ME/CFS state itself.
Consequence: If a real IgE-sensitized subset exists, it would be identifiable with antigen-specific (not standard) IgE testing and might — speculatively — respond to anti-IgE or mast-cell-targeted strategies; if it does not exist, the “allergic to the infection” intuition can be set aside in favour of the non-IgE mast cell model. Either way this is a research question, not a basis for current clinical action.
(Origin: literature synthesis.) (Certainty: 0.30.) Independent of whether the IgE targets the infecting antigen, infection itself raises the risk of new allergic disease at population scale. A multinational cohort (n = 836,164, propensity-matched) found COVID-19 associated with incident allergic disease (hazard ratio 1.20 overall; asthma 2.25; allergic rhinitis 1.23) (Oh et al. 2024) (certainty 0.85), replicated in a separate propensity-matched cohort (Clarion et al. 2026) (certainty 0.70). The mechanistic route is plausible: epithelial injury releases alarmins (IL-33, IL-25, TSLP) that polarize Th2 responses and expand ILC2s, with epigenetic “scars” sustaining the Th2 bias (Filippatos et al. 2025). ME/CFS patients do show a Th2/Tc2 cytokine bias (Skowera et al. 2004) (certainty 0.55) — but, per Total and Allergen-Specific IgE Are Normal in ME/CFS: A Replicated Null, without the IgE elevation that classically accompanies Th2 skewing. This dissociation (Th2 bias present, IgE normal) is itself informative: it argues that any post-infectious allergic shift in ME/CFS is IgE-independent (though a sub-threshold IgE response below assay detection cannot be formally excluded, and would leave a residual IgE possibility open).
Falsifiable prediction: Prospective follow-up of acute COVID-19 or documented tick-bite cohorts will show that individuals who develop ME/CFS have a higher incidence of new clinician-diagnosed allergic disease in the year after infection than those who recover — but that this excess is driven by Th2-axis symptoms rather than by measurable rises in total IgE. Falsified if new-allergy incidence is equal between those who develop ME/CFS and those who recover, or if it is entirely explained by total-IgE elevation.
Consequence: This reframes the popular intuition usefully: the robust, large-sample finding is that infection can trigger allergic disease in the general population, not that ME/CFS is an IgE-allergic disease. The former is well-evidenced; the latter is not.
(Origin: brainstorm.) The mechanistic chain from mast cell activation to cognitive and neuropsychiatric symptoms is described in animal and in-vitro models: histamine activates microglia via the H1 receptor, generating Nox1-derived reactive oxygen species and dopaminergic neurotoxicity (Rocha et al. 2016); mast cells disrupt the blood-brain barrier and activate microglia via histamine, tryptase, and PAR2 in a bidirectional loop (Lakatos and Rosta 2025); and CRH (the stress mediator) triggers intracranial mast cell degranulation within minutes (Theoharides et al. 1995). What is unresolved — and central to the antigen-specific IgE hypothesis — is whether the mast cell activation that plausibly contributes to ME/CFS “brain fog,” mood lability, and dysautonomia is driven by IgE cross-linking of FcεRI (the allergic route) or by the non-IgE triggers (substance P, CRH, IL-33, MRGPRX2) that dominate the MCAS literature. The replicated normal IgE in ME/CFS (Total and Allergen-Specific IgE Are Normal in ME/CFS: A Replicated Null) tilts the answer toward non-IgE activation, but no study has measured the FcεRI-versus-non-IgE contribution in ME/CFS directly, in blood or in brain. A concrete non-IgE candidate already proposed in this book is the GPCR-autoantibody-to-mast-cell sensitization loop (GPCR Autoantibody-Mediated Mast Cell Sensitization — Bidirectional Amplification Loop), which would activate mast cells without any IgE involvement.
Falsifiable prediction: Measuring mast-cell mediators (urinary N-methylhistamine, serum tryptase, PGD2) before and after a standardized provocation (e.g. a tilt challenge or cognitive-stress task) alongside antigen-specific IgE will show that ME/CFS patients with mast-cell symptoms degranulate without a corresponding antigen-specific IgE signal — elevated mediators in the absence of detectable IgE-antigen pairing — distinguishing them from classical allergic patients who show mediator release coupled to specific IgE. Falsified if mediator release in symptomatic ME/CFS patients consistently co-occurs with, and tracks the titre of, a measurable antigen-specific IgE.
Consequence: Distinguishing IgE from non-IgE mast cell activation matters therapeutically: an IgE-dominant subset might respond to anti-IgE therapy (a research-stage idea only), whereas a non-IgE-dominant population would not — so resolving this question would prevent a category of futile treatment trials. No clinical action follows from it today.
1 Counterarguments: Why IgE May Be a Red Herring in ME/CFS
The hypothesis above is presented for completeness and because it has public traction, but the strongest reading of the evidence is that antigen-specific IgE is unlikely to be a major driver of ME/CFS. Three independent counterarguments converge on this conclusion.
(Origin: brainstorm.) (Certainty: 0.60.) Theoharides and colleagues argue that mast cell activation in chronic inflammatory conditions is predominantly non-IgE-driven — via substance P, corticotropin-releasing hormone (CRH), IL-33, and the mas-related G-protein-coupled receptor MRGPRX2 (covered elsewhere in the MCAS sections of this book). This framework accounts for the full observation set with fewer assumptions than the IgE hypothesis: the Th2 cytokine bias (Skowera et al. 2004) follows from IL-33/TSLP driving ILC2 and Th2 responses without requiring IgE; the replicated normal IgE (Repka-Ramirez et al. 2001) (Kowal et al. 2002) is expected because no IgE is needed for activation; high self-reported allergy with normal eosinophil cationic protein is consistent with histamine-release symptoms that mimic allergy; stress exacerbation is explained by CRH directly degranulating mast cells (Theoharides et al. 1995); and downstream mast-cell neuroinflammation (Lakatos and Rosta 2025) (Rocha et al. 2016) occurs regardless of which trigger activated the mast cell. By parsimony, the non-IgE model is the better-supported default; the IgE hypothesis would need to demonstrate something uniquely IgE-explained (a food- or aeroallergen-specific flare pattern, or directly measured antigen-specific IgE correlating with severity) to displace it.
Consequence: For most ME/CFS patients, mast-cell-related symptoms are more likely driven by stress, inflammatory signalling, and nerve-fibre activation than by classical allergy — so standard allergy testing targets the wrong trigger. Antihistamines may still relieve symptoms by blocking histamine receptors downstream regardless of how the mast cell was triggered, but neither testing nor antihistamines should be expected to address the core disease.
(Origin: brainstorm.) (Certainty: 0.45.) Every study documenting anti-spike IgE measured acute or convalescent COVID-19, not chronic post-infectious illness (Tan et al. 2022) (Meltendorf et al. 2022) (Portilho et al. 2024). IgE class-switching to viral antigens during an acute Th2-skewed response is typically transient: short-lived IgE plasmablasts decline as antigen is cleared. By the time ME/CFS is established (\(\geq\) 6 months post-infection), the spike-specific IgE may have decayed to baseline — unless antigen persists in tissue reservoirs (a separate, unproven question). This interpretation is consistent with Giménez-Orenga et al. (2025), who found anti-spike IgE higher in post-COVID condition than in prepandemic ME/CFS (Giménez-Orenga et al. 2025): a decaying exposure marker, not a marker of the chronic disease state.
Consequence: The allergic-type antibody some people make against SARS-CoV-2 during acute illness may simply fade afterwards, making it largely irrelevant to ME/CFS symptoms months or years later.
(Origin: brainstorm.) (Certainty: 0.50.) The best-established model of tick-induced antigen-specific IgE — alpha-gal syndrome — presents as delayed anaphylaxis (urticaria, angio-oedema, gastrointestinal distress, anaphylaxis) 2–6 hours after mammalian-meat ingestion (Platts-Mills et al. 2025) (Wilson et al. 2024) (Nunen 2015). This profile is qualitatively distinct from ME/CFS (post-exertional malaise, orthostatic intolerance, cognitive dysfunction, unrefreshing sleep). The extensive alpha-gal clinical literature does not describe PEM, orthostatic intolerance, or the characteristic ME/CFS cognitive pattern in alpha-gal patients. Note the version of the IgE hypothesis being tested here is chronic low-grade sensitization (A Minority Post-Infectious Subset May Carry Antigen-Specific IgE to Spike or Tick Antigens), not acute reactivity — so the relevant test is not whether alpha-gal patients have ME/CFS-like acute reactions, but whether tick-induced antigen-specific IgE is associated with chronic ME/CFS at all. The tick→IgE link is real, but the type and location of mast cell activation it produces (systemic degranulation to a carbohydrate antigen) differs from what an ME/CFS mechanism would require (chronic, perivascular, BBB-adjacent).
Falsifiable prediction: If the tick→IgE→ME/CFS pathway were correct, alpha-gal syndrome cohorts would show higher-than-expected rates of ME/CFS diagnosis or ME/CFS-like symptoms; a cross-sectional survey of alpha-gal cohorts would detect this. Falsified if alpha-gal cohorts show ME/CFS prevalence no higher than the general population.
Consequence: People with tick-bite-related meat allergy do not appear to develop ME/CFS, a clue that tick bites probably do not cause ME/CFS through the allergic pathway.
2 A Decisive, Low-Cost Test of the Hypothesis
(Origin: brainstorm.) The central uncertainty — whether antigen-specific IgE marks ME/CFS disease state or merely past exposure — is resolvable with a single, inexpensive serosurvey using assays that already exist (Tan et al. 2022) (Meltendorf et al. 2022). Measure anti-spike (S1, S2, RBD) IgE, anti-nucleocapsid IgE, and IgG4 across three groups: (a) post-COVID ME/CFS, (b) post-COVID recovered without ME/CFS, and (c) prepandemic ME/CFS. Primary endpoint: anti-spike IgE titre by group. Secondary: correlation with clinical severity, mast-cell mediators (tryptase, histamine, PGD2), and a neurocognitive battery. The design must control for time-since-infection, acute COVID severity, atopic background, and vaccination history — because Giménez-Orenga et al. (2025) already suggest the signal tracks exposure (Giménez-Orenga et al. 2025).
Falsifiable prediction: Anti-spike IgE titres will not differ between post-COVID ME/CFS and post-COVID recovered groups after controlling for acute severity and time-since-infection — which would confirm the exposure-marker interpretation and effectively close the IgE-as-driver hypothesis. The contrary result (higher titres in the ME/CFS group, correlating with severity) would re-open it.
Consequence: A straightforward blood-test study could determine whether the allergic-type response to SARS-CoV-2 is a cause of ongoing illness or just a scar of past infection — directly informing whether antihistamine- or anti-IgE-type approaches are even worth trialling.
2.1 Measurement Caveats for Any Future Serosurvey
(Origin: brainstorm.) (Certainty: 0.55.) Two measurement problems must be controlled in any IgE study. First, ME/CFS patients consistently self-report more allergy than controls while serological markers (total IgE (Repka-Ramirez et al. 2001), allergen-specific IgE (Kowal et al. 2002), eosinophil cationic protein) remain normal; stratifying by self-reported atopy therefore risks misclassifying non-IgE mast-cell activation as allergy, diluting or inflating any true IgE signal. Objective IgE measurement plus validated mast-cell-mediator panels — not patient-reported history — must define the groups. Second, many anti-spike IgE assays use recombinant spike with denatured or linear epitopes (especially Western-blot formats); by analogy to the well-recognised conformational-versus-linear epitope problem in food-allergy diagnostics, IgE detected against linear epitopes may not bind native trimeric spike and therefore may not cross-link FcεRI to trigger degranulation. A functionally meaningful serosurvey requires native, conformationally intact spike (e.g. cell-surface or pseudotype display).
Consequence: When an ME/CFS patient reports “allergies,” it may reflect stress- or inflammation-driven mast-cell activity rather than true IgE allergy — and some positive anti-spike IgE results in the literature may be laboratory artifacts — so both the disease definition and the assay format must be chosen carefully before any conclusion is drawn.
The proposal that ME/CFS reflects an IgE-mediated allergy to spike or tick-borne antigens assembles real components into an unvalidated whole. Each link can be evidenced in isolation — spike-specific IgE exists in acute COVID (Tan et al. 2022), tick bites generate antigen-specific IgE via alpha-gal (Platts-Mills et al. 2025), infection raises allergic-disease incidence at population scale (Oh et al. 2024), and mast-cell mediators drive BBB-adjacent neuroinflammation in animal models (Lakatos and Rosta 2025) — yet the assembled pathway has never been measured in ME/CFS, and the only direct ME/CFS data point the other way: total and allergen-specific IgE are replicated-normal (Total and Allergen-Specific IgE Are Normal in ME/CFS: A Replicated Null). The weight of evidence favours the competing, more parsimonious model in which mast-cell involvement in ME/CFS is non-IgE-driven (The Non-IgE MCAS Paradigm Explains Every Observation Without Antigen-Specific IgE), reinforced by the GPCR-autoantibody-to-mast-cell loop already proposed in this book (GPCR Autoantibody-Mediated Mast Cell Sensitization — Bidirectional Amplification Loop). Two further constraints — that documented anti-spike IgE is an acute-phase signal likely to decay (Documented Anti-Spike IgE Is an Acute-Phase Signal That Likely Decays in Chronic Illness) and that alpha-gal syndrome’s phenotype does not match ME/CFS (Alpha-Gal Syndrome’s Symptom Profile Does Not Match ME/CFS) — make a tick/spike-IgE driver still less likely. The hypothesis is nonetheless cheaply falsifiable: a three-group anti-spike IgE serosurvey (A Three-Group Anti-Spike IgE Serosurvey Would Open or Close This Hypothesis) would close or re-open it in a single study. Until such direct data exist, the honest verdict is that antigen-specific IgE is an unstudied possibility confined, at most, to a minority subset (A Minority Post-Infectious Subset May Carry Antigen-Specific IgE to Spike or Tick Antigens) — not an established mechanism.
Consequence: The popular intuition that ME/CFS patients are “allergic to” their triggering infection is not supported by current evidence; for most patients the relevant mast-cell mechanism is non-allergic, so allergy testing and antihistamines should not be expected to address the core disease — though one inexpensive blood-test study could settle the question definitively.